PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 153 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $67,000 | +31.4% | 10,933 | 0.0% | 0.00% | – |
Q1 2019 | $51,000 | +10.9% | 10,933 | 0.0% | 0.00% | – |
Q4 2018 | $46,000 | -33.3% | 10,933 | 0.0% | 0.00% | – |
Q3 2018 | $69,000 | -21.6% | 10,933 | 0.0% | 0.00% | – |
Q2 2018 | $88,000 | +7.3% | 10,933 | 0.0% | 0.00% | – |
Q1 2018 | $82,000 | – | 10,933 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
SEARLE & CO. | 60,000 | $349,000 | 0.34% |
TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |